Evidence map›Paper›PMID 30860979›Full record

ArticleAging2019

FoxD2-AS1 promotes glioma progression by regulating miR-185-5P/HMGA2 axis and PI3K/AKT signaling pathway.

Wei Ni, Yaoxiong Xia, Yuxu Bi, Fan Wen, Dong Hu, Lin Luo

RetractedOpen access · greenAbstract readRetracted Publication
In one paragraph

Article in Aging, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 41 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 1 pooled it
6.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 1 synthesis or guideline pooled it, 91 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Wei Ni *Department of Neurosurgery, The Third Affiliated Hospital of Kunming Medical University, Kunming 650118, Yunan Province, China.
Yaoxiong Xia *Department of Radiation Oncology, The Third Affiliated Hospital of Kunming Medical University, Kunming 650118, Yunan Province, China.
Yuxu BiDepartment of Neurosurgery, The Third Affiliated Hospital of Kunming Medical University, Kunming 650118, Yunan Province, China.
Fan WenDepartment of Neurosurgery, The Third Affiliated Hospital of Kunming Medical University, Kunming 650118, Yunan Province, China.
Dong HuDepartment of Neurosurgery, The Third Affiliated Hospital of Kunming Medical University, Kunming 650118, Yunan Province, China.
Lin LuoDepartment of Neurosurgery, The Third Affiliated Hospital of Kunming Medical University, Kunming 650118, Yunan Province, China.
Kunming Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimsThe present study was aimed at exploring the role of long noncoding RNA (lncRNA) FOXD2-AS1 in the development and progression of glioma and the underlying mechanism of FOXD2-AS1/miR-185-5p/HMGA2 network in glioma via regulation of PI3K/Akt signaling pathway.

methodsMicroarray analysis was used for preliminary screening for candidate lncRNAs and mRNAs in glioma tissues. qRT-PCR and Western blot were used to determine the expression of FOXD2-AS1. The potential effects of FOXD2-AS1 on the viability, mobility and apoptosis of glioma cells were evaluated using MTT assay, Transwell assays and flow cytometry. The xenograft tumor model was performed to examine the influence of the lncRNA FOXD2-AS1/miR-185-5p/HMGA2 network on the biological functions of glioma cells. Luciferase assay and immunoprecipitation assay were examined to dissect molecular mechanisms.

resultsLncRNA FOXD2-AS1 was overexpressed in human glioma, and upregulated FOXD2-AS11 expression indicated higher WHO grade (p < 0.05). MiR-185-5p was downregulated, whereas HMGA2 was upregulated in glioma tissues in comparison with para-carcinoma tissues. FOXD2-AS1 could regulate the expression of HMGA2 via miR-185-5p. Knockdown of FOXD2-AS1 significantly inhibited proliferation and metastatic potential of glioma cells, whereas endogenous expression FOXD2-AS1 inhibited the glioma cell activity through targeting HMGA2.

conclusionslncRNA FOXD2-AS1 acted as a sponge of miR-185-5p and influenced the PI3K/Akt signaling pathway through regulating HMGA2. LncRNA FOXD2-AS1 modulated HMGA2 and PI3K/Akt downstream signaling through sponging miR-185-5p, thereby promoting tumorigenesis and progression of glioma.

Indexed as

AnimalsCell Line, TumorCell MovementCell ProliferationForkhead Transcription FactorsGene Expression Regulation, NeoplasticGliomaHMGA2 ProteinHumansMiceMice, NudeMicroRNAsNeoplasms, ExperimentalPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktRNA, Long NoncodingForkhead Transcription FactorsFOXD2 protein, humanHMGA2 ProteinHMGA2 protein, humanMicroRNAsMIRN185 microRNA, humanPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktRNA, Long NoncodingFOXD2-AS1gliomalncRNAmetastasisproliferation

Identifiers

PMID30860979
PMCPMC6428107
OpenAlexW2922013917

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.